Noble Corporation (NYSE: NE) announced that David W. Williams, Chairman, President and Chief Executive Officer, will present at the Credit Suisse 20th Annual Energy Summit being held at the Vail Cascade Resort & Spa in Vail, Colorado. The presentation is scheduled to begin at 1:10 p.m. U.S. Central Standard Time on Wednesday, February 25, 2015. On Thursday shares of Noble Corp plc (NYSE:NE) closed at $19.51. Company’s sales growth for last 5 years was -2.40%.
Calgon Carbon Corporation (NYSE: CCC) announced results for the fourth quarter and year ended December 31, 2014. Income from operations for the fourth quarter of 2014 was $18.8 million versus $15.8 million for the comparable period in 2013. Net income for the fourth quarter of 2014 was $12.1 million, or $0.23 per common share on a fully diluted basis, versus $11.0 million, or $0.20 per common share on a fully diluted basis, for the fourth quarter of 2013. Calgon Carbon Corporation (NYSE:CCC) in last trading activity moved up 7.49% to close at $21.37. Company weekly performance is 7.71% while its quarterly performance stands at 2.44%. Calgon Carbon Corporation (NYSE:CCC) is -7.61% away from its 52 week high.
Select Medical Holdings Corporation (NYSE: SEM) declared a quarterly dividend of $0.10 per share, or $0.4 annualized. The dividend will be payable on March 11, 2015, to stockholders of record on March 4, 2015, with an ex-dividend date of March 2, 2015. On last trading day Select Medical Holdings Corporation (NYSE:SEM) moved down -1.34% to close at $14.01. Its volatility for the week is 2.31% while volatility for the month is 2.68%. SEM’s sales growth for past 5 years was 6.70% and its EPS growth for past 5 years was 86.40%. Select Medical Holdings Corporation (NYSE:SEM) monthly performance is 1.16%.
Roth Capital assumed coverage on shares of CECO Environmental Corp. (NASDAQ:CECE) in a research note issued to investors on Tuesday. The firm issued a neutral rating and a $15.50 price target on the stock. CECO Environmental Corp. (NASDAQ:CECE) has 0.20% insider ownership while its institutional ownership stands at 53.40%. In last trading activity company’s stock closed at $14.61.
On 17 February, Celsus Therapeutics (NASDAQ:CLTX), announced the results from C012013, a Phase II, double-blind, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of MRX-6 cream 2% in a pediatric population with mild to moderate atopic dermatitis. On last trading day Celsus Therapeutics Plc (NASDAQ:CLTX) moved down -1.81% to close at $1.13. Its volatility for the week is 9.28% while volatility for the month is 4.85%. Celsus Therapeutics Plc (NASDAQ:CLTX) monthly performance is -79.94%.